Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01927 | 34560015 | Lancet Gastroenterol Hepatol | Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. | 2021 | Details |
| A01928 | 34559251 | Arch Toxicol | Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptation. | 2021 | Details |
| A01929 | 34559098 | Medicine (Baltimore) | The efficacy and safety of acupuncture in nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2021 | Details |
| A01930 | 34558862 | Hepatol Commun | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01931 | 34558856 | Hepatol Commun | Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. | 2021 | Details |
| A01932 | 34558854 | Hepatol Commun | RORα Enhances Lysosomal Acidification and Autophagic Flux in the Hepatocytes. | 2021 | Details |
| A01933 | 34558853 | Hepatol Commun | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. | 2021 | Details |
| A01934 | 34558849 | Hepatol Commun | Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With Obesity. | 2021 | Details |
| A01935 | 34558842 | Hepatol Commun | Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. | 2021 | Details |
| A01936 | 34558838 | Hepatol Commun | Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. | 2021 | Details |
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | 2021 | Details |
| A01938 | 34558829 | Hepatol Commun | Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. | 2021 | Details |
| A01939 | 34558828 | Hepatol Commun | PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. | 2021 | Details |
| A01940 | 34558817 | Hepatol Commun | Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. | 2021 | Details |
| A01941 | 34558644 | Mol Med Rep | PPARγ attenuates hepatic inflammation and oxidative stress of non‑alcoholic steatohepatitis via modulating the miR‑21‑5p/SFRP5 pathway. | 2021 | Details |
| A01942 | 34558178 | J Cell Mol Med | Five-in-One: Simultaneous isolation of multiple major liver cell types from livers of normal and NASH mice. | 2021 | Details |
| A01943 | 34557660 | JHEP Rep | Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. | 2021 | Details |
| A01944 | 34557535 | Front Cardiovasc Med | Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. | 2021 | Details |
| A01945 | 34557498 | Front Med (Lausanne) | Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. | 2021 | Details |
| A01946 | 34557398 | Pediatr Gastroenterol Hepatol Nutr | The PNPLA3 rs738409 Variant but not MBOAT7 rs641738 is a Risk Factor for Nonalcoholic Fatty Liver Disease in Obese U.S. Children of Hispanic Ethnicity. | 2021 | Details |
| A01947 | 34557397 | Pediatr Gastroenterol Hepatol Nutr | Investigation of Thiol/Disulfide Balance in Obese Rats with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01948 | 34557367 | Cureus | Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. | 2021 | Details |
| A01949 | 34557366 | Cureus | The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). | 2021 | Details |
| A01950 | 34556715 | Sci Rep | Ruminant fat intake improves gut microbiota, serum inflammatory parameter and fatty acid profile in tissues of Wistar rats. | 2021 | Details |
| A01951 | 34555423 | J Hepatol | Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. | 2021 | Details |
| A01952 | 34555422 | J Hepatol | NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. | 2021 | Details |
| A01953 | 34555346 | Lancet Gastroenterol Hepatol | Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. | 2021 | Details |
| A01955 | 34555255 | Liver Int | COVID-19, adaptative immune response and metabolic-associated liver disease. | 2021 | Details |
| A01956 | 34554611 | J Paediatr Child Health | Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. | 2021 | Details |
| A01957 | 34553836 | Obesity (Silver Spring) | Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. | 2021 | Details |
| A01958 | 34552988 | Biomed Res Int | Identification of Key Genes and Immune Infiltrate in Nonalcoholic Steatohepatitis: A Bioinformatic Analysis. | 2021 | Details |
| A01959 | 34552789 | Arab J Urol | Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study. | 2021 | Details |
| A01960 | 34552698 | World J Hepatol | Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. | 2021 | Details |
| A01961 | 34552561 | Front Endocrinol (Lausanne) | GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. | 2021 | Details |
| A01962 | 34551612 | Future Med Chem | Xanthohumol alleviates T2DM-induced liver steatosis and fibrosis by mediating the NRF2/RAGE/NF-κB signaling pathway. | 2021 | Details |
| A01963 | 34551462 | J Complement Integr Med | Non-alcoholic fatty liver disease - discussed under the light of Unani medicine. | 2021 | Details |
| A01964 | 34550043 | Adipocyte | Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. | 2021 | Details |
| A01965 | 34549824 | FASEB J | Creld2 function during unfolded protein response is essential for liver metabolism homeostasis. | 2021 | Details |
| A01966 | 34549558 | Adv Clin Exp Med | A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice. | 2021 | Details |
| A01967 | 34549325 | Eur Radiol | Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. | 2021 | Details |
| A01968 | 34548787 | Clin Interv Aging | NAFLD in the Elderly. | 2021 | Details |
| A01969 | 34548598 | Sci Rep | Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. | 2021 | Details |
| A01970 | 34547477 | Ann Hepatol | Alternative splicing and liver disease. | 2021 | Details |
| A01971 | 34547464 | Mol Ther | METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. | 2021 | Details |
| A01972 | 34547171 | Liver Int | The role of hepatic lipid composition in obesity-related metabolic disease. | 2021 | Details |
| A01973 | 34546515 | Obes Surg | Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A01974 | 34546514 | Obes Surg | Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis. | 2021 | Details |
| A01975 | 34546125 | Radiology | Quantification of Liver Fat Content with CT and MRI: State of the Art. | 2021 | Details |
| A01976 | 34544714 | BMJ Case Rep | Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism. | 2021 | Details |
| A01977 | 34543756 | Clin Res Hepatol Gastroenterol | Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. | 2021 | Details |
| A01978 | 34543735 | Diabetes Metab | Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. | 2021 | Details |
| A01979 | 34543610 | Lancet | Liver cirrhosis. | 2021 | Details |
| A01980 | 34543583 | Arch Physiol Biochem | Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. | 2021 | Details |
| A01981 | 34543448 | Clin Pharmacol Ther | Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. | 2021 | Details |
| A01982 | 34543321 | PLoS One | Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data. | 2021 | Details |
| A01983 | 34542962 | Clin Lab | Association between Serum Free Fatty Acids to HDL-Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study. | 2021 | Details |
| A01985 | 34541964 | Expert Opin Pharmacother | Management of non-alcoholic fatty liver disease in patients with sarcopenia. | 2021 | Details |
| A01986 | 34540943 | Visc Med | Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). | 2021 | Details |
| A01987 | 34540134 | Kans J Med | Bariatric Metabolic Surgery Reduced Liver Enzyme Levels in Patients with Non-Alcohol Fatty Liver Disease. | 2021 | Details |
| A01988 | 34537988 | Hepatology | Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. | 2021 | Details |
| A01989 | 34537584 | Curr Opin Pharmacol | Genetic risk scores and personalization of care in fatty liver disease. | 2021 | Details |
| A01990 | 34537182 | Anal Biochem | Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease? | 2021 | Details |
| A01991 | 34536973 | FEBS Lett | Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36. | 2021 | Details |
| A01992 | 34536498 | Life Sci | Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway. | 2021 | Details |
| A01993 | 34536264 | Anat Rec (Hoboken) | Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease. | 2021 | Details |
| A01994 | 34536163 | J Med Ultrason (2001) | Quantitative assessment of liver steatosis using ultrasound: dual-energy CT. | 2021 | Details |
| A01995 | 34535985 | Hepatol Commun | Genome-Wide Association Study of NAFLD Using Electronic Health Records. | 2021 | Details |
| A01996 | 34535644 | Nat Commun | A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. | 2021 | Details |
| A01997 | 34535562 | J Pharmacol Exp Ther | Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. | 2021 | Details |
| A01998 | 34534913 | Redox Biol | Hepatic Regulator of G Protein Signaling 6 (RGS6) drives non-alcoholic fatty liver disease by promoting oxidative stress and ATM-dependent cell death. | 2021 | Details |
| A01999 | 34534894 | Clin Nutr | Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. | 2021 | Details |
| A02000 | 34533904 | Am J Manag Care | Baffled by NAFLD: the horse might be out of the barn but should not take us for a ride. | 2021 | Details |
| A02001 | 34533882 | Cancer Sci | Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. | 2021 | Details |
| A02002 | 34533632 | J Gastroenterol | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02003 | 34533606 | Eur Radiol | Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. | 2021 | Details |
| A02004 | 34533266 | Hepatol Res | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02005 | 34533252 | J Biochem Mol Toxicol | Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation. | 2021 | Details |
| A02006 | 34533249 | Phytother Res | The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. | 2021 | Details |
| A02007 | 34532996 | Hepatol Commun | TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. | 2021 | Details |
| A02008 | 34532981 | Hepatol Commun | The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis. | 2021 | Details |
| A02009 | 34532024 | Food Sci Nutr | ω3PUFAs improve hepatic steatosis in postnatal overfed rats and HepG2 cells by inhibiting acetyl-CoA carboxylase. | 2021 | Details |
| A02010 | 34531465 | Sci Rep | Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A02011 | 34531312 | Drug Metab Dispos | Strategies to Diagnose Non-Alcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. | 2021 | Details |
| A02012 | 34531129 | Dig Liver Dis | Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation. | 2021 | Details |
| A02013 | 34530928 | Microbiome | Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. | 2021 | Details |
| A02014 | 34530818 | BMC Med | Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: a 10-year prospective study of 0.5 million adults. | 2021 | Details |
| A02015 | 34530527 | Clin Mol Hepatol | Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. | 2021 | Details |
| A02017 | 34529948 | Biochem Pharmacol | Ubiquitin pathways regulate the pathogenesis of chronic liver disease. | 2021 | Details |
| A02018 | 34529585 | Physiol Int | The "GG" genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease. | 2021 | Details |
| A02020 | 34529067 | JAMA Netw Open | Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02021 | 34528882 | Turk J Gastroenterol | Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. | 2021 | Details |
| A02022 | 34528723 | Aliment Pharmacol Ther | Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A02023 | 34528679 | Int J Epidemiol | Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study. | 2022 | Details |
| A02025 | 34528223 | Horm Metab Res | Clinical Value and Role of miR-129-5p in Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A02026 | 34527673 | Front Cell Dev Biol | Lack of miR-379/miR-544 Cluster Resists High-Fat Diet-Induced Obesity and Prevents Hepatic Triglyceride Accumulation in Mice. | 2021 | Details |
| A02027 | 34527094 | Gastroenterology Res | Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. | 2021 | Details |
| A02028 | 34526911 | Front Physiol | Metabolic Changes of Hepatocytes in NAFLD. | 2021 | Details |
| A02029 | 34526786 | Infect Drug Resist | Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. | 2021 | Details |
| A02030 | 34526653 | Commun Biol | Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. | 2021 | Details |
| A02031 | 34525916 | Curr Med Chem | Beneficial Effects of Dietary Polyphenols in the Prevention and Treatment of NAFLD: Cell-Signaling Pathways Underlying Health Effects. | 2022 | Details |